23andMe (ME) - 2025 Q1 - Quarterly Results

EXHIBIT 99.1 23andMe Reports First Quarter Fiscal 2025 Financial Results SOUTH SAN FRANCISCO, Calif., August 8, 2024 -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal year 2025 (FY25), which ended June 30, 2024. Key Results and Recent Developments • Reported total revenue of $40 million in the first quarter of fiscal 2025, a decrease of approximately 34% over the same period in the prior year primarily ...